FDA is asking an advisory panel whether Merck's Keytruda needs more data before a regulatory decision for triple-negative breast cancer can be made • Source: Shutterstock
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
